Alzamend Neuro, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Alzamend Neuro shows severe financial deterioration with cash declining 31% to $2.7M, accounts payable surging 193%, and R&D expenses increasing 231% year-over-year. The company faces imminent going concern issues given current burn rate of ~$6M annually and limited cash runway of approximately 5-6 months.
Red Flags Detected (6)
Cash decreased 31% from $3.9M to $2.7M in 9 months
Accounts payable increased 193% from $635K to $1.86M indicating cash flow stress
Net loss increased 75% year-over-year to $5.9M for nine months
3 more red flags detected
Key Takeaways
Company is burning through cash at unsustainable rate with limited runway remaining
Significant increase in R&D spending suggests clinical trial advancement but strains finances
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.